INTRODUCTION
Certain hereditary platelet disorders have been characterized by a deficiency of specific platelet membrane glycoproteins. In one of these disorders, Bernard-Soulier syndrome, the platelets lack the platelet membrane glycoprotein (GP)' Ib (1-3), and in another, Glanzmann's thrombasthenia, there is a deficiency of GPIIb and GPIIIa (1) (2) (3) (4) (5) (6) Montgomery. Received for publication 24 September 1982 and in revised form 8 November 1982. 1 Abbreviations used in this paper: AP-1 and AP-2, antiplatelet 1 and 2, respectively; GP, glycoprotein.
developed monoclonal antibodies to these glycoproteins (7) (8) (9) (10) , and in one of these studies (7), thrombasthenic platelets were evaluated in a washed platelet assay by using a monoclonal antibody.
Although the diagnosis of Bernard-Soulier syndrome is suggested by giant platelets and an absence of ristocetin-induced platelet aggregation (1, 2, 11) , the specific diagnosis is confirmed by detailed platelet membrane glycoprotein analysis (1, 2, 12) . Unfortunately, Bernard-Soulier platelets are difficult to separate from whole blood; thus, the functional and glycoprotein analyses are not easily performed. In Glanzmann's thrombasthenia, studies demonstrate reduced or absent platelet aggregation, decreased clot retraction, a prolonged bleeding time (1), and reduced platelet GPIIb and GPIIIa (1, 2, 12, 13) . Platelet membrane glycoprotein analysis is not a routine laboratory determination; thus, the majority of patients suspected of having these diagnoses may not have the glycoprotein deficiency confirmed.
In the process of preparing monoclonal antibodies to platelet membrane glycoproteins, we developed a rapid semiquantitative assay that can be performed on <1 ml of whole blood. Because whole blood is used, this obviates the preparation of platelet-rich plasma, which may be difficult to prepare from patients with Bernard-Soulier syndrome. In this report we describe the development of these monoclonal antibodies and their use in this diagnostic assay. (14) . Fusion was accomplished with 50% polyethylene glycol 1,500. Hypoxanthine-aminopterin-thymidine medium selection was carried out (14) and hybridized cells grown in hypoxanthine-thymidine medium for 2-3 wk. Positive hybridomas were selected by an enzyme-linked immunoabsorbent assay by using partially purified platelet membrane glycoproteins (GPIIb/IIIa complex and GPIb). In addition, a microtiter screening assay for the inhibition of ristocetin-induced platelet aggregation was developed. Each well contained 100 ul of formalin-fixed platelets incubated for 2 h with 50 ,ul of tissue culture fluid. Normal plasma (15 ul) and 5 Ml of ristocetin (30 mg/ml) were added and the microtiter plate agitated overnight. The presence or absence of aggregation was noted. Absent aggregation suggested an antibody directed against GPIb. Positive hybrids were cloned by limiting cell dilution on feeder layers of peritoneal exudate cells (15) .
METHODS
Ascites tumors. Clones were grown to sufficient density and 5 X 105 cells injected intraperitoneally into "Pristane primed" (BALB/c X DBA/2 F1 mice. Mice were tapped for ascites fluid usually after 2-3 wk. Subsequent ascites tumors were produced from master cultures of the clones and not sequentially passed as ascites tumors.
Identification of specific monoclonal antibody to GPIb and GPIIb/IIIa. Monoclonal antibody was prepared from the ascites fluid by three sequential 50% ammonium sulfate precipitations, dialyzed against potassium phosphate buffer (0.01 M, pH 7.4), and applied to Protein A-Sepharose. Elution from the Protein A used Tris glycine buffer that was prepared by adding 2 M glycine HCl to 0.01 M Tris in order to bring the pH to 2.2. The pH of the eluted material was returned to neutrality (pH 7-7.5) with 1 M K3HPO4. The IgG was labeled with Na'25I by the chloramine T method, as described previously (16) . Crossed immunoelectrophoresis was carried out against Triton X-100 solubilized platelet proteins, as previously described (12) , except that labeled monoclonal antibody was incorporated into the second dimension along with the unlabeled rabbit antiplatelet antisera (17) . Although the monoclonal antibodies were not precipitating, they bound to antigens contained in the precipitates produced by the rabbit antisera, thereby substantiating the immunologic reactivity of the monoclonal antibodies.
Inhibition of ristocetin-induced platelet aggregation. The titer of antibody to GPIb was assessed by diluting the monoclonal antibody and incubating 10 Al of this IgG with 400 Al of formalin-fixed platelets before performing a ristocetin cofactor assay, as previously described (16 Crossed immunoelectrophoresis of Triton X-100 solubilized platelets was carried out against rabbit anti-human platelet antisera (unlabeled) and labeled monoclonal antibody (AP-1 or AP-2). Slides were stained and autoradiography performed, permitting the identification of the specificity of the monoclonal antibodies.
IgG). Triton X-100 extracts of human platelets were subjected to crossed immunoelectrophoresis against unlabeled rabbit antiplatelet antibody and labeled AP-1 or AP-2. The slides were stained with Coomassie Blue R and autoradiographed. The radiolabeled precipitates therefore identified the reactivity of the monoclonal antibodies as shown in Fig. 1 Monoclonal antibody binding assay on whole blood samples. Fig. 2 illustrates the results on the 23 normal individuals, 6 patients with Glanzmann's thrombasthenia, and 3 patients with Bernard-Soulier syndrome. With whole blood, the Glanzmann's patients had normal AP-1 binding, whereas the Bernard-Soulier patients had <2% binding. AP-2 binding studies demonstrated that the Glanzmann patients had <13% AP-2 binding, whereas the Bernard-Soulier patients had normal AP-2 binding. Of note are the three Glanzmann's patients who had negligible AP-2 binding, whereas there were three others that had greatly reduced AP-2 binding. None of the former group had demonstrable GPIIb/IIIa on glycoprotein analysis, whereas the latter three had reduced but detectable GPIIb/IIIa on glycoprotein analysis. 
Monoclonal Whole Blood Assay of Hereditary Platelet Disorders
Quantitative AP-1 and AP-2 monoclonal antibody binding assay on platelet-rich plasma. With plateletrich plasma (250,000/mm3), two of the Bernard-Soulier patients and one of the Glanzmann patients were compared with serial dilutions of normal platelet-rich plasma. The severe Glanzmann patient bound normal AP-1 but less AP-2 than a 1:256 dilution of normal platelet-rich plasma. Conversely, the Bernard-Soulier patients bound increased AP-2 (approximately twice normal) but less AP-1 than a 1:256 dilution of normal platelet-rich plasma.
DISCUSSION
The diagnosis of Glanzmann's thrombasthenia and Bernard-Soulier syndrome is based upon characteristic platelet function testing (1, 4, 5) , crossed immunoelectrophoresis of Triton X-100 solubilized platelets (12, 13) , or detailed glycoprotein analysis (1, 2, 12) . In one study, GPIb was quantitated by densitometric scanning of periodic acid -Schiff-stained polyacrylamide gels of platelet glycoproteins (18 Although other investigators (7) have studied isolated platelets from patients with Glanzmann's thrombasthenia with a monoclonal antibody to GPIIb/IIIa, whole blood was not tested. We were able to detect the surface platelet glycoprotein deficiency with monoclonal antibodies to specific platelet glycoproteins in a whole blood assay. This is particularly helpful in diagnosing Bernard-Soulier syndrome, in which platelet separation is difficult due to the increased platelet size (1, 3) . We found the assay to give consistent results even on 36-h-old refrigerated whole blood anticoagulated with acid citrate dextrose. Thus, shipping of samples is possible for this determination. Whereas, glycoprotein analysis is a moderately tedious determination, results with our method are available within 2 h of receipt of the sample. Although not stud-s ied, this technique would permit the diagnosis of these disorders in newborns, where platelet function testing is often impossible due to sample volume. This assay, on the other hand, requires <1 ml of whole blood.
Although more precise quantitation of glycoproteins is possible if platelet-rich plasma is used, the degree of separation of normal and abnormal platelets in the more easily performed whole blood assay makes it a better screening test. This whole blood assay is capable of distinguishing between type II Glanzmann's thrombasthenic patients and severe type I thrombasthenic patients. In two instances, the Glanzmann patients had been thought to be severe until this assay was performed. Subsequent glycoprotein analysis demonstrated detectable GPIIb/IIIa, thereby substantiating their type II classification.
There is no consensus as to whether the platelets from Bernard-Soulier syndrome patients should be studied at equivalent platelet counts or equivalent platelet mass. It was of interest that although these patients were thrombocytopenic, their AP-2 binding was within the normal range on the whole blood assay. When the platelets were run at equivalent concentration to normal platelets (platelet-rich plasma), the 
